Obalon To Present at Two Upcoming Institutional Investor Conferences
SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that Bill Plovanic, President and Chief Executive Officer, will present corporate overviews at the following investor conferences:
Stifel 2019 Healthcare Conference
Wednesday, November 20, 2019, Presentation time 9:10am ET Lotte New York Palace Hotel, New York City Webcast Available at: http://wsw.com/webcast/stifel18/obln/
Canaccord Genuity Medical Technologies & Diagnostics Forum
Thursday, November 21, 2019, Presentation time 2:00pm ET The Westin Grand Central Hotel, New York City Webcast Available at: http://wsw.com/webcast/canaccord37/obln/
Live audio webcasts of the presentation can be accessed through the links above. Replays of the webcasts will be available for 90 days following each presentation.
About Obalon Therapeutics, Inc. Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc.
Investor Contact: Bill Plovanic President & Chief Executive Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected]
Source: Obalon Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ukraine's Y-Park Gains Global Recognition as First Dedicated Legal AI Innovation Hub
- New Jersey Digital Agency Synaryverse Integrates AI Into Marketing, Development, and Creative Services
- Data Center Youngbloods Expands Global Talent Pipeline as Demand for Digital Infrastructure Accelerates
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Stifel, Canaccord Genuity, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share